title: Efficacy, safety, and current applications of brimonidine.
abstract: BACKGROUND
  The use of brimonidine to lower intraocular pressure has been the subject of considerable investigation. Variations of the initially approved drug including agents of a lower concentration (Alphagan P 0.15 and 0.1%, Allergan, Inc., Irvine, CA, USA) and a fixed-combination mating brimonidine with timolol (Combigan, Allergan) evolved the marketing and application of this therapy.
  
  
  OBJECTIVE
  We review available evidence regarding the efficacy and side effect profile of brimonidine as well as its role in glaucoma management.
  
  
  CONCLUSIONS
  Brimonidine is an important component of topical glaucoma treatment that is most limited by local ocular intolerance.
authors.affiliation: Wills Eye Institute, Instructor, Jefferson Medical College Anna and William Goldberg Glaucoma Service and Research Center, 840 Walnut St. Ste 1130, Philadelphia, PA 19107, USA. sfudemberg@willseye.org
authors.forename: Scott J
authors.initials: SJ
authors.lastname: Fudemberg
authors.forename: Corey
authors.initials: C
authors.lastname: Batiste
authors.forename: L Jay
authors.initials: LJ
authors.lastname: Katz
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000068438:Brimonidine Tartrate; D004338:Drug Combinations; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D009798:Ocular Hypertension / Q000188:drug therapy; D009883:Ophthalmic Solutions; D011810:Quinoxalines / Q000008:administration & dosage* / Q000009:adverse effects; D013999:Timolol / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D004338:Drug Combinations; D009883:Ophthalmic Solutions; D011810:Quinoxalines; D000068438:Brimonidine Tartrate; D013999:Timolol